ReNeuron Group plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ReNeuron Group plc
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.
Aimmune Therapeutics secures agreement with NHS for “step change” in treating peanut allergy.
Also, AstraZeneca presents more promising data for its COVID-19 antibody cocktail Evusheld and Novavax says its vaccine is able to neutralize the Omicron variant.
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.